Core Viewpoint - The company, Shuanglu Pharmaceutical, is expected to report a continued net loss for 2025, which is projected to be larger than the previous year, leading to a significant drop in its stock price on February 2, 2025 [1][3]. Financial Performance - The company anticipates a net profit loss of between -290 million to -200 million yuan for 2025, representing a year-on-year decline of 170.03% to 291.54% [3]. - The expected non-recurring net profit loss is projected to be between -70 million to -40 million yuan, indicating a year-on-year decrease of 148.58% to 185.02% [3]. - In 2024, Shuanglu Pharmaceutical reported revenue of approximately 660 million yuan, a decline of 35.15% year-on-year, with a net profit of about -7.407 million yuan, marking a shift from profit to loss [3]. Sales and Margins - The sales gross margin decreased by approximately 10% due to a decline in the unit price of some products, which was a significant factor in the performance change [4]. - The company faced substantial impacts from centralized drug procurement policies, leading to lower prices and reduced overall sales revenue despite increased sales volume through procurement channels [4]. Investment Losses - Non-recurring losses, including confirmed investment losses and changes in the fair value of financial assets, are expected to reduce net profit by approximately 200 million yuan, contributing to the increased loss [6]. - The chairman, Xu Mingbo, has voluntarily committed to cover the irrecoverable portion of investment losses, with an initial payment of 50 million yuan to the company [6]. Strategic Response - The company plans to accelerate the launch of new products and enhance market expansion efforts, particularly focusing on solid oral dosage forms and strengthening its marketing network in response to changes in the pharmaceutical market due to procurement policies [5].